Hypertension and kidney disease: A deadly connection

被引:35
作者
Barri Y.M. [1 ]
机构
[1] Division of Nephrology and Transplantation, Baylor University Medical Center, Dallas, TX 75246
关键词
Chronic Kidney Disease; Diabetic Nephropathy; Blood Pressure Control; Hemodialysis Patient; Blood Pressure Goal;
D O I
10.1007/s11886-006-0098-7
中图分类号
学科分类号
摘要
Kidney disease may be the cause or a consequence of hypertension. Hypertension affects 25% of the adult population in the United States. Similarly, chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been steadily increasing in incidence because of the increasing age of the US population and rise in the incidence of risk factors, including hypertension. Substantial evidence supports the notion that elevated blood pressure is the most significant risk factor for the development of CKD. Microalbuminuria has been shown to be the early marker of hypertensive renal disease. Furthermore, therapy to reduce microalbuminuria was associated with delay in the progression of renal disease. Black Americans are at higher risk for developing hypertensive nephrosclerosis than whites. Hypertension is a major risk factor for cardiovascular events in patients with CKD and ESRD and those who have undergone renal transplantation. Studies have documented that elevated serum creatinine and CKD are risk factors for a cardiovascular event. Tight blood pressure control has been shown to reduce microalbuminuria and proteinuria and to delay progression of renal disease. Tailoring the choice of antihypertensive medication to the clinical setting to achieve a blood pressure goal is critical in reducing complications from this deadly connection. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:411 / 417
页数:6
相关论文
共 40 条
[31]  
Zager P.G., Nikolic J., Brown R.H., Et al., U" curve association of blood pressure and mortality in hemodialysis patients, Medical Kidney Int, 54, pp. 561-569, (1998)
[32]  
Liu M., Takahashi H., Morita Y., Et al., Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in hemodialysis patients, Nepbrol Dial Transplant, 18, (2003)
[33]  
First M.R., Neylan J.F., Rocher L.L., Et al., Hypertension after renal transplantation, J Am Soc Nephrol, 4, SUPPL. 1, pp. 30-36, (1994)
[34]  
Texter S.C., Canzanello V.J., Talor S.J., Et al., Cyclosporine-induced hypertension after transplantation, Mayo Clin Proc, 69, pp. 1182-1193, (1994)
[35]  
Veenstra D.L., Best J.H., Hornberger J., Et al., Incidence and long-term cost of steroid related side effects after renal transplantation, Am J Kidney Dis, 33, pp. 829-839, (1999)
[36]  
Opelz G., Wujciak T., Ritz E., Association of chronic kidney graft failure with recipient blood pressure, Kidney Int, 53, pp. 217-222, (1998)
[37]  
Ruggenenti P., Perico N., Mosconi L., Et al., Calcium channel blockers protect transplant patients from cyclosporine induced daily renal hypoperfusion, Kidney Int, 43, pp. 706-711, (1993)
[38]  
Midtvedt K., Hartmann A., Hypertension after kidney transplantation: Are treatment guidelines emerging, Nephrol Dial Transplant, 17, pp. 1166-1169, (2002)
[39]  
Midtvedt K., Hartmann A., Foss A., Et al., Sustained improvement of renal graft function for 2 years in hypertensive renal transplant recipients treated with nifedipine compared to lisinopril, Transplantation, 72, pp. 1787-1792, (2001)
[40]  
Olyaei A.S., deMottos A.M., Bennett W.M., A practical guide to the management of hypertension in renal transplant recipients, Drugs, 58, pp. 1011-1027, (1999)